RxDoctor Payments Data

Kenneth Vargas, MD

Internal Medicine · Nashville, TNNPI 1639249774

Payments from drug & device makers

$13,555in general payments, 2019–2025

Across 815 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Pfizer$1K
  • AbbVie$1K
  • Amgen$1K
  • Lilly USA, LLC$997
  • AstraZeneca$855
  • plus $6K from 47 others

What the payments were for

  • Food & beverage$13,555100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,555 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$90,267
Medicare patients
299
Services billed
1,528

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$102,956
MounjaroTirzepatide74$79,965
OzempicSemaglutide59$77,253
JanuviaSitagliptin Phosphate86$70,796
CreonLipase/Protease/Amylase21$63,289
FarxigaDapagliflozin Propanediol56$49,466
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$48,622
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$40,588
JardianceEmpagliflozin15$20,053
RybelsusSemaglutide17$19,514
MyrbetriqMirabegron26$17,492
InvokanaCanagliflozin16$12,424
TrulicityDulaglutide12$11,749
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen378$9,143
LinzessLinaclotide12$7,529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$1,322$109,972110 claims
Novo NordiskOzempic, Rybelsus$2,211$96,76776 claims
Lilly USA, LLCMounjaro, Trulicity$997$91,71486 claims
AbbVieCreon, Linzess, Synthroid$1,045$74,32668 claims
MerckJanuvia$468$70,79686 claims
AstraZenecaFarxiga, Brilinta$855$54,19268 claims
GileadGenvoya$79$48,62212 claims
GSKTrelegy Ellipta$822$40,58837 claims
Boehringer IngelheimJardiance, Combivent Respimat$353$25,29326 claims
Astellas Pharma US IncMyrbetriq$444$17,49226 claims
Johnson & JohnsonInvokana$119$12,42416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →